NASDAQ$LGND
Ligand Pharmaceuticals Incorporated · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for Q4 and full year 2022, with total revenues of $50.4 million for the quarter.
Ligand reported a net loss of $14.5 million for Q4 2022, with total revenues of $50.4 million. The results were impacted by a $24.8 million deferred tax asset valuation allowance and a $44.2 million non-cash gain from short-term investments. Adjusted net income was $23.5 million, or $1.36 per diluted share.
- Total revenues for the fourth quarter of 2022 were $50.4 million, compared to $56.4 million for the same period in 2021.
- Royalties for the fourth quarter of 2022 were $22.0 million, compared to $17.6 million for the same period in 2021.
- Net loss from continuing operations for the fourth quarter of 2022 was $14.5 million, or $0.86 per share, compared to $3.2 million, or $0.19 per share, for the same period in 2021.
- As of December 31, 2022, Ligand had cash, cash equivalents and short-term investments of $211.9 million.
Headline financials
Revenue & EPS history
Ligand · Revenue · Quarterly
$50.4M
Revenue by segment
Ligand · $22M total across 1 segment · Q4 2022
- Royalties$22M+25.3%100.0%
Forward guidance
Ligand is increasing 2023 financial guidance introduced at its Investor and Analyst Day held on December 13, 2022. They now expect 2023 royalties of $74 million to $78 million, sales of Captisol of $21 million and contract revenue of $25 million. These revenue components result in total revenue of $120 million to $124 million.
Tailwinds
- 2023 royalties of $74 million to $78 million (previously $72 million to $76 million)
- Sales of Captisol of $21 million (unchanged)
- Contract revenue of $25 million (unchanged)
- Total revenue of $120 million to $124 million (previously $118 million to $122 million)
- Adjusted diluted EPS of $3.30 to $3.45 (previously $3.10 to $3.30).
Headwinds
- Due to the unpredictable nature of the pandemic and related Captisol sales, Ligand excludes Captisol for remdesivir from guidance
- Will update investors as orders are received and shipped each quarter.
- Uncertainty regarding the commercial performance of products.
- Potential delays in clinical testing.
- Unexpected adverse side effects.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+18.7%
Q4 2013
Best reaction
-21.6%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.5% | +5.2% | +12.9% | |
| Q4 2025 | +2.6% | +6.7% | +2.1% | |
| Q3 2025 | +9.3% | +9.6% | -2.9% | |
| Q1 2025 | -3.2% | +0.0% | +0.4% | |
| Q4 2024 | +0.6% | +0.2% | -6.4% | |
| Q3 2024 | +3.7% | +3.3% | +6.8% | |
| Q2 2024 | -4.9% | +2.1% | +5.1% | |
| Q1 2024 | +10.3% | +19.8% | +13.1% | |
| Q4 2023 | +13.3% | +5.8% | -1.8% | |
| Q3 2023 | +2.8% | +3.8% | +16.3% | |
| Q2 2023 | +6.7% | +1.4% | -4.2% | |
| Q1 2023 | +5.2% | +3.2% | -0.2% | |
| Q4 2022 | +5.9% | +3.0% | -2.1% | |
| Q3 2022 | +12.8% | +31.3% | +6.0% | |
| Q2 2022 | +5.7% | +9.5% | -3.5% | |
| Q1 2022 | -2.9% | -13.0% | -9.1% | |
| Q4 2021 | -16.3% | -19.7% | -8.7% | |
| Q3 2021 | +7.8% | +4.9% | -6.9% | |
| Q2 2021 | -8.1% | -10.0% | -7.4% | |
| Q1 2021 | -9.5% | -10.5% | -22.3% | |
| Q4 2020 | +1.7% | +17.6% | -18.5% | |
| Q3 2020 | -0.2% | +5.4% | +3.4% | |
| Q2 2020 | +0.6% | +0.4% | -11.9% | |
| Q1 2020 | +3.2% | +6.8% | +22.1% | |
| Q4 2019 | +3.3% | +2.8% | +16.7% | |
| Q3 2019 | -7.4% | -1.4% | -4.9% | |
| Q2 2019 | -14.8% | -11.5% | -14.7% | |
| Q1 2019 | -3.3% | -4.1% | -14.6% | |
| Q4 2018 | -2.7% | +1.8% | -10.0% | |
| Q3 2018 | -2.7% | -8.9% | -10.7% | |
| Q2 2018 | +9.8% | +7.7% | +13.0% | |
| Q1 2018 | +7.3% | +13.2% | +26.4% | |
| Q4 2017 | +0.0% | -1.9% | +3.7% | |
| Q3 2017 | -4.9% | -1.3% | -8.4% | |
| Q2 2017 | +5.7% | +2.5% | +9.4% | |
| Q1 2017 | -2.9% | +0.2% | +1.2% | |
| Q4 2016 | -2.8% | +1.3% | +1.5% | |
| Q3 2016 | -2.7% | +3.1% | +10.8% | |
| Q2 2016 | -7.4% | -13.2% | -20.2% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +5.1% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +4.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | +18.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q1 2013 | +1.7% | — | — | |
| Q4 2012 | +7.4% | — | — | |
| Q3 2012 | +10.8% | — | — | |
| Q2 2012 | -8.8% | — | — | |
| Q4 2011 | -8.8% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q3 2011 | -21.6% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | -2.4% | — | — | |
| Q2 2010 | -3.6% | — | — | |
| Q1 2010 | -9.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro